Developers Seek to Deliver Drugs in High Doses Subcutaneously

As Therapeutics and Demographics Converge Developers Seek to Deliver Drugs in High Doses Subcutaneously

Economic and Logistical Benefits are Compelling According to Greystone Research Associates

(Amherst, NH) – As the trend favoring biological drugs as a percent of all drugs continues, the number of injectables that exceed 1 mL per dose, the de facto limit for comfortable and safe patient self-administration, is also increasing. Drugs that require dosing in higher volumes are typically infused in a healthcare setting. Managed care providers and healthcare strategists have taken notice and several foresee a changing healthcare delivery landscape that will challenge efforts at cost containment and alter healthcare infrastructure.

The reason is that the demographics of patient populations and the current trend in therapeutic drug development are converging to create an increasingly steep demand curve for infusion. The costs and logistics of this convergence are a major driver of the efforts to develop and commercialize high volume drug delivery products that can be administered subcutaneously.

A number of developers have been designing and testing drug delivery devices that are capable of administering drugs in volumes of 20 mL or higher subcutaneously. Several of these firms have partnered with pharmaceutical companies such as Ferring, CSL Behring and Amgen. More than a dozen clinical stage products are winding their way through the development process.

The evolving high volume injectables sector is detailed in a new and comprehensive report researched and written by Greystone Research Associates. High Volume Subcutaneous Drug Delivery analyzes the global market for existing and emerging injectable drugs requiring volumes above the practical limits of traditional injection devices. The report also analyzes demand drivers, development factors, market considerations, and strategic and economic factors, and provides profiles of market sector participants.

More information is available at http://www.greystoneassociates.org

ENDS

© Scoop Media